FDA Inspection 564301 — Celgene Corporation D.B.A. Abraxis Bioscience
The FDA completed an inspection of Celgene Corporation D.B.A. Abraxis Bioscience on Feb 18, 2009 in Melrose Park, IL. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 18, 2009
- Fiscal Year
- 2009
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Melrose Park, IL (United States)